Department of Gastroenterology and Digestive Endoscopy Center, The Second Hospital of Jilin University, Changchun, 130000, PR China.
Department of Gastroenterology and Digestive Endoscopy Center, The Second Hospital of Jilin University, Changchun, 130000, PR China.
Eur J Pharmacol. 2022 Sep 5;930:175152. doi: 10.1016/j.ejphar.2022.175152. Epub 2022 Jul 11.
Colorectal cancer (CRC) is a multifactorial disease. The incidence of this type of cancer in younger patients has increased in recent years, and more strategies are needed to prevent and delay the progression of CRC. Probiotics play an adjunctive role in the prevention and treatment of CRC and can not only prevent the onset and delay the progression of disease but also reduce the side effects after the application of anti-cancer drugs. The anti-cancer effect of individual probiotics has been extensively studied, and the exact curative effect of various probiotics has been found, but the anti-cancer effect of mixed probiotics is still not well summarized. In this review, we discuss the positive effects of mixed probiotics on CRC and the related mechanisms of action, especially VSL#3 (VSL Pharmaceuticals, Inc., Gaithersburg, MD, USA), thus providing new ideas for the treatment of CRC. Moreover, we suggest the need to search for more therapeutic possibilities, especially via the research and application of synbiotics and postbiotics.
结直肠癌（CRC）是一种多因素疾病。近年来，年轻患者中这种癌症的发病率有所增加，因此需要更多的策略来预防和延缓 CRC 的进展。益生菌在 CRC 的预防和治疗中起辅助作用，不仅可以预防疾病的发生和延缓疾病的进展，还可以减少抗癌药物应用后的副作用。个别益生菌的抗癌作用已得到广泛研究，已发现各种益生菌的确切疗效，但混合益生菌的抗癌作用仍未得到很好的总结。在这篇综述中，我们讨论了混合益生菌对 CRC 的积极影响及其相关作用机制，特别是 VSL#3（VSL 制药公司，马里兰州盖瑟斯堡），从而为 CRC 的治疗提供了新的思路。此外，我们建议需要寻找更多的治疗可能性，特别是通过对合生元和后生元的研究和应用。
